High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer

Cancer Journal

Volumn 6, Issue SUPPL. 2, 2000, Pages

  Rodenhuis, S ^a   Huitema, A D R ^b   Van Dam, F S A M ^a   De Vries, E G E ^c   Beijnen, J H ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Breast cancer; Cognitive function; Cyclophosphamide; High dose chemotherapy; Peripheral blood progenitor cell transplatation; Thiotepa

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; MITOXANTRONE; THIOTEPA;

BREAST CANCER; CANCER ADJUVANT THERAPY; CELL TRANSPLANTATION; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG MEGADOSE; HUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; THIOTEPA;

EID: 0033941833     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Bezwoda WR. Randomised controlled trial of high dose chemotherapy (HD-CMVp) vs standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer [abstract 4]. Proc Am Soc Clin Oncol 1999;18:2a.
2. Hortobagyi GN, Buzdar AU, Champlin R et al. Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer - a randomized trial [abstract 471]. Proc Am Soc Clin Oncol 1998;17:471.
3. Rodenhuis S, Richel DJ, Van der Wall E et al. A randomised trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive anxillary lymph node involvement. Lancet 1998;352:515-521.
4. Peters W, Rosner G, Vrendenburgh J et al. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9144/ NCIC MA-13 [abstract 2]. Proceedings of the American Society of Clinical Oncology 1999;18:1a.
5. The Scandinavian Breast Cancer Study Group 9401. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy [abstract 3]. Proc Am Soc Clin Oncol 1999;18:2a.
6. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-2489.
7. Van Dam FSAM, Schagen SB, Muller M et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-218.
8. Stadmauer EA, O'Neill A, Goldstein LJ et al. Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the "Philadelphia" Intergroup Study (BPT-1) [abstract 1]. Proc Am Soc Clin Oncol 1999;18:1a.
9. De Vries EGE, Mastenbroek CC, Rodenhuis S. High dose chemotherapy for breast cancer. Ann Int Med 1997;126:917-918.
10. Huitema ADR, Tibben MM, Kerbusch TH et al. Simultaneous determination of thiotepa, cyclophosphamide and some metabolites in plasma using capillary gas chromatography. J Chromatogr B 1998;716:177-186.
11. Van Maanen RJ, Van Ooijen RD, Zwikker JW et al. Determination of N, N′, N″-triethylentiophosphoramide and its active metabolite N′N′, N″-triethylenphosphoramide in plasma and urine using capillary gas chromatography. J Chromatogr B 1998;719:103-112.